LONDON, Nov. 24 The European autoimmune diseasediagnostics market has demonstrated sustained growth due to advances indetection technology and automation. Active consolidation is occurring in themarket, promoting technology and product integration. However, the lack ofclarity with regard to reimbursement policies for autoimmune diagnostic testspersists, posing a challenge to market expansion.
New analysis from Frost & Sullivan (http://www.drugdiscovery.frost.com),European Autoimmune Disease Diagnostics Market, finds that the market earnedrevenues of $513.5 million in 2008 and estimates this to reach $722.0 millionin 2015.
"The development of novel biomarker panels has accelerated the diagnosisof many autoimmune complications," notes Frost & Sullivan Research AnalystSuraj Ramanathan. "Exhaustive R&D by many universities and researchorganisations has yielded promising results in the use of multiple biomarkersfor autoimmune disease diagnosis."
The ability to screen a patient with multiple biomarkers associated withseveral autoimmune diseases has been shown to improve the accuracy of thediagnosis and has had a significant positive influence on the autoimmunedisease diagnostics market. Such novel biomarker panels will continue to offeran added advantage to physicians in the diagnosis of these complications.
Despite the advances in detection technology, the generalised lack ofawareness among the public with regard to autoimmune diseases presents achallenge to market growth.
"Such low levels of awareness may derive from the rarity of manyautoimmune complications among the general population," explains Ramanathan."Many patients in Europe, unable to find a proper treatment for theircondition, are consequently switching to traditional methods such as orientalmedicine."
The need is, therefore, to boost patient awareness. This can be achievedthrough extensive workshops and disease awareness programmes.
"In conjunction with medical research organisations and hospitals,manufacturers should establish awareness programmes and interactive workshopsfor the public," advises Ramanathan. "These could highlight the prevalence ofautoimmune diseases, while encouraging physicians to interact with the publicon the symptoms, etiology and progression of autoimmune diseases."
If you are interested in a virtual brochure, which provides manufacturers,end users and other industry participants with an overview of the Europeanautoimmune disease diagnostics market, then send an e-mail to Patrick Cairns,Corporate Communications, at [email protected]
, with your full name,company name, title, telephone number, company e-mail address, companywebsite, city, state and country. Upon receipt of the above information, anoverview will be sent to you by e-mail.
Strategic Analysis of the European Autoimmune Disease Diagnostics Marketis part of the Drug Discovery & Clinical Diagnostics Growth PartnershipServices programme, which also includes research in the following markets:European POC Connectivity Market, European Immunoassay Diagnostics Market,Western European IVD Markets, and Eastern European IVD Markets. All researchincluded in subscriptions provide detailed market opportunities and industrytrends that have been evaluated following extensive interviews with marketparticipants. Interviews with the press are available.
Frost & Sullivan, the Growth Partnership Company, partners with clients toaccelerate their growth. The company's TEAM Research, Growth Consulting andGrowth Team Membership(TM) empower clients to create a growth-focused culturethat generates, evaluates and implements effective growth strategies. Frost &Sullivan employs over 45 years of experience in partnering with Global 1000companies, emerging businesses and the investment community from more than 30offices on six continents. For more information about Frost & Sullivan'sGrowth Partnership Services, visit http://www.frost.com.Strategic Analysis of the European Autoimmune Disease Diagnostics Market M2DC Contact: Patrick Cairns Corporate Communications P: +27 18 468 2315 E: [email protected]
SOURCE Frost & Sullivan